

#DYK Did you know?

RNA therapies target any gene, offering broad therapeutic potential beyond traditional drugs targeting proteins



Four main RNA therapies in clinical trials: mRNA Vaccines, ASOs, RNAi, and Aptamers



mRNA vaccines lead, proven by their success against COVID-19



Pfizer and BioNTech pioneered the mRNA COVID-19 vaccine, inspiring others




Innovative delivery methods like lipid nanoparticles extend half-life and reduce immunotoxicity




Global mRNA trials target more infectious diseases (AIDS, hepatitis B), cancer, metabolic diseases and rare diseases (DMD, Hemophilia)

Trial Distribution:



Targeted Therapeutic areas:



2019 - 2023 RNA therapy trials (CAGR: 20.6%)



Fastest CAGR: Asia-Pacific (26.7%)



Trial Leaders: US, UK, Australia



Phase II (>40%)



Protein replacement therapies gaining attention among innovators

75% of RNA M&A deals are acquisitions, led by the US (25% mergers)

Significant funding supports mRNA advancements